Visual Outcomes in Patients Contralaterally Implanted With PanOptix Pro and Clareon Vivity Compared to Bilateral Implantation of PanOptix Pro
Key facts
- Who runs it
- Brian Shafer
- Where
- Alexandria, Bala-Cynwyd, Baltimore, Bozeman, and Plymouth Meeting, United StatesSee the 5 sites
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 346 people, planned
- Started
- 5 Aug 2025
- Expected to end
- 1 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Clareon PanOptix Pro and Clareon Vivity Intraocular Lens
- Clareon PanOptix Pro Intraocular Lenses
- Record updated
- 22 September 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Bilateral diagnosis of age-related cataracts
- Planned bilateral cataract removal by phacoemulsification with either:
- Contralateral implantation of Clareon PanOptix Pro/PanOptix Pro Toric in one eye and Clareon Vivity/Vivity Toric in the fellow eye, or
- Bilateral implantation of Clareon PanOptix Pro/PanOptix Pro Toric
- Expected best monocular corrected distance visual acuity (BCDVA) of 0.1 logMAR (Snellen 20/25) or better in both eyes postoperatively, as determined by the surgeon
- Residual astigmatism expected to be ≤0.50 diopters in both eyes postoperatively (using toric IOLs or arcuate incisions as needed)
- Normal ocular findings aside from cataracts
Who cannot take part
- Previous history of any ocular surgery, including corneal refractive surgery
- Any planned simultaneous or combined procedures at the time of cataract surgery (e.g., MIGS)
- Preexisting macular disease or other retinal degenerative disease expected to cause vision loss
- Severe dry eye disease
- Any condition (in the investigator's opinion) that may affect study endpoints
- History of amblyopia or monofixation syndrome with poor stereoscopic vision
- Any active ocular infection or inflammation
- Glaucoma
- Nystagmus or strabismus
- Zonular laxity or dehiscence, pseudoexfoliation
- Subjects desiring monovision
- Total corneal higher-order aberrations (HOA) greater than 0.6 microns
- Participation in another clinical study that could interfere with study results
- Pregnant, breastfeeding, or planning to become pregnant during the study (as determined by verbal inquiry)
Where in United States
- Vance Thompson VisionAlexandria, United StatesEnrolling by invitation
- Main Line Surgery CenterBala-Cynwyd, United StatesEnrolling by invitation
- VIP Eye CareBaltimore, United StatesEnrolling by invitation
- Vance Thompson VisionBozeman, United StatesEnrolling by invitation
- Shafer Vision InstitutePlymouth Meeting, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
Title:
Read full original descriptionShow less
Visual Outcomes in Patients Contralaterally Implanted with PanOptix Pro and Clareon Vivity Compared to Bilateral Implantation of PanOptix Pro
Sponsor:
Brian Shafer, MD, Shafer Vision Institute
Objective:
To compare visual outcomes and patient-reported satisfaction in cataract patients receiving either:
Contralateral implantation (PanOptix Pro in one eye, Clareon Vivity in the other)
Bilateral PanOptix Pro implants
Key hypotheses:
Contralateral implantation is non-inferior for binocular best-corrected distance visual acuity (BCDVA) at 4 m.
Contralateral implantation yields superior visual disturbance outcomes (less halo, glare, starburst).
Design:
Prospective, randomized, double-masked, two-arm, multicenter study
N = 346 subjects (173 per arm)
5 surgeons across 4 sites
All patients undergo bilateral phacoemulsification aiming for emmetropia
Randomized 1:1 to:
Arm 1: PanOptix Pro (dominant eye) + Clareon Vivity (non-dominant eye)
Arm 2: Bilateral PanOptix Pro
Surgical Details:
Femtosecond laser optional
Second eye surgery ≤4 weeks after first
Toric IOLs or arcuate incisions for residual astigmatism ≤0.50 D
Biometry with ARGOS, IOLMaster 700, or Lenstar
Toric alignment with ORA, Callisto, etc.
Assessments:
Visual acuity at 4 m, 66 cm, 40 cm, 33 cm in photopic and mesopic conditions
Defocus curves, contrast sensitivity (with/without glare)
Manifest refraction
Patient-reported outcomes via IOLSAT and QUVID questionnaires
Masking: subjects and assessors unaware of IOL assignments
Endpoints (at 3 months):
Primary: Binocular BCDVA (4 m)
Secondary: DCIVA, DCNVA, UDVA, UIVA, UNVA, defocus curves, refractive outcomes, visual disturbance scores
Exploratory: Mesopic VA, low contrast VA, contrast sensitivity, satisfaction scores
Eligibility Criteria:
Adults with bilateral age-related cataracts
Plan for bilateral phacoemulsification
Expected postop monocular BCDVA ≤0.1 logMAR (20/25)
Residual astigmatism ≤0.50 D
Exclusions include corneal pathology, macular disease, glaucoma, prior ocular surgery, amblyopia, severe dry eye, high HOA (>0.6 um), monovision preference, active infection/inflammation, pregnancy
Statistics:
Non-inferiority margin: 0.1 logMAR
Superiority testing for visual disturbances
Step-down testing hierarchy for primary and secondary outcomes
Sample size powered for 80% at α=0.05, accounting for 10% dropout
Two-proportion Z-tests for dysphotopsia rates
Safety Monitoring:
Adverse Events (AEs) and Serious Adverse Events (SAEs) captured
Definitions, severity grading, and reporting procedures specified
Protocol deviations documented and reported per IRB requirements
Data Handling:
Data anonymized via subject numbers
Stored securely (locked cabinets, password-protected systems)
Study registered at ClinicalTrials.gov
Visit Schedule:
Screening: Consent, eligibility, history
1st \& 2nd Eye Surgery Visits
3-Month Post-Op Visit: Comprehensive visual assessments, questionnaires, AE review
The 2 groups in the trial
- Contralateral PanOptix Pro and Clareon VivityTreatment being tested
Subjects randomized to this arm will receive bilateral cataract surgery with contralateral implantation: Alcon Clareon PanOptix Pro or PanOptix Pro Toric IOL in one eye and Alcon Clareon Vivity or Vivity Toric IOL in the fellow eye. The Vivity IOL will be implanted in the dominant eye, with all surgeries targeting emmetropia. Residual astigmatism will be managed to ≤0.50 diopters using toric IOLs or arcuate incisions as needed.
Treatment: Clareon PanOptix Pro and Clareon Vivity Intraocular Lens
- Bilateral PanOptix ProExisting treatment, for comparison
Subjects randomized to this arm will receive bilateral cataract surgery with implantation of Alcon Clareon PanOptix Pro or PanOptix Pro Toric IOLs in both eyes. All eyes will be targeted for emmetropia, and residual astigmatism will be controlled to ≤0.50 diopters using toric IOLs or arcuate incisions as appropriate.
Treatment: Clareon PanOptix Pro Intraocular Lenses
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 22 September 2025